New Prescribing Instructions Tighten Use of Controversial Alzheimer’s Drug
THURSDAY, July 8, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer’s medication Aduhelm that will likely limit its use. When first approved a month ago, the FDA said Biogen’s monthly IV drug was for all Alzheimer’s patients. TheContinue Reading